Importantly, the review also notes that individual responses to incretin-based therapies can vary substantially, and weight regain commonly occurs if treatment is discontinued, highlighting the chronic nature of obesity management
OVER 100,000 TREES PLANTED AND COUNTING
Allergic/anaphylactic reactions to ingredients
It is not yet FDA-approved but has shown remarkable weight loss results in phase 2 trials, with participants losing up to 24.2% of body weight at the highest dose over 48 weeks
Packer M, Zile Michael R, Kramer Christopher M, Baum Seth J, Litwin Sheldon E, Menon V, et al
These entities are not subject to the stringent quality control, safety standards, or regulatory oversight required for legitimate medications